BIOGEN INC. Increase (Decrease) in Other Operating Liabilities
BIOGEN INC. (BIIB) reported Increase (Decrease) in Other Operating Liabilities of -$248.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2026-02-06
- BIOGEN INC. increase (decrease) in other operating liabilities for the quarter ending 2011-12-31 was -$16.56M.
- BIOGEN INC. increase (decrease) in other operating liabilities for the quarter ending 2011-09-30 was $32.11M, a 4435.17% increase year-over-year.
- BIOGEN INC. increase (decrease) in other operating liabilities for the quarter ending 2011-06-30 was -$90.22M, a 3307.43% decline year-over-year.
- BIOGEN INC. increase (decrease) in other operating liabilities for the quarter ending 2011-03-31 was $38.44M, a 1.05% increase year-over-year.
- BIOGEN INC. increase (decrease) in other operating liabilities for fiscal 2025 was -$248.00M.
- BIOGEN INC. increase (decrease) in other operating liabilities for fiscal 2024 was -$178.70M.
- BIOGEN INC. increase (decrease) in other operating liabilities for fiscal 2023 was -$73.90M.
- BIOGEN INC. increase (decrease) in other operating liabilities for fiscal 2022 was -$92.00M.
| Period end | Increase (Decrease) in Other Operating Liabilities 3 month | Increase (Decrease) in Other Operating Liabilities 6 month | Increase (Decrease) in Other Operating Liabilities 9 month | Increase (Decrease) in Other Operating Liabilities 12 month | Increase (Decrease) in Other Operating Liabilities 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | -$248.00M 10-K · filed 2026-02-06 | ||||
| 2024-12-31 | -$178.70M 10-K · filed 2026-02-06 | ||||
| 2023-12-31 | -$73.90M 10-K · filed 2026-02-06 | ||||
| 2022-12-31 | -$92.00M 10-K · filed 2025-02-12 | ||||
| 2021-12-31 | -$144.50M 10-K · filed 2024-02-14 | ||||
| 2020-12-31 | -$137.10M 10-K · filed 2023-02-15 | ||||
| 2019-12-31 | -$43.30M 10-K · filed 2022-02-03 | ||||
| 2018-12-31 | -$135.40M 10-K · filed 2021-02-03 | -$16.30M 10-K · filed 2019-02-06 | |||
| 2017-12-31 | -$79.00M 10-K · filed 2020-02-06 | -$2.40M 10-K · filed 2018-02-01 | |||
| 2016-12-31 | $69.50M 10-K · filed 2019-02-06 | ||||
| 2015-12-31 | $83.20M 10-K · filed 2018-02-01 | $93.60M 10-K · filed 2016-02-03 | |||
| 2014-12-31 | $68.70M 10-K · filed 2017-02-02 | $94.78M 10-K · filed 2015-02-04 | |||
| 2013-12-31 | $161.70M 10-K · filed 2016-02-03 | $318.51M 10-K · filed 2014-02-06 | |||
| 2012-12-31 | $34.11M 10-K · filed 2015-02-04 | ||||
| 2011-12-31 | -$16.56M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-06 | $15.55M derived: sum of 2 quarters · filed 2014-02-06 | -$74.68M derived: sum of 3 quarters · filed 2014-02-06 | -$36.23M 10-K · filed 2014-02-06 | |
| 2011-09-30 | $32.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-28 | -$58.12M derived: sum of 2 quarters · filed 2011-10-28 | -$19.68M 10-Q · filed 2011-10-28 | -$43.55M derived: sum of 4 quarters · filed 2013-02-05 | |
| 2011-06-30 | -$90.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-26 | -$51.78M 10-Q · filed 2011-07-26 | -$75.66M derived: sum of 3 quarters · filed 2013-02-05 | -$74.95M derived: sum of 4 quarters · filed 2013-02-05 | |
| 2011-03-31 | $38.44M 10-Q · filed 2011-04-21 | $14.57M derived: sum of 2 quarters · filed 2013-02-05 | $15.28M derived: sum of 3 quarters · filed 2013-02-05 | $18.09M derived: sum of 4 quarters · filed 2013-02-05 | |
| 2010-12-31 | -$23.87M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | -$23.16M derived: sum of 2 quarters · filed 2013-02-05 | -$20.35M derived: sum of 3 quarters · filed 2013-02-05 | $17.69M 10-K · filed 2013-02-05 | |
| 2010-09-30 | $708.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-28 | $3.52M derived: sum of 2 quarters · filed 2011-10-28 | $41.56M 10-Q · filed 2011-10-28 | -$42.46M derived: sum of 4 quarters · filed 2012-02-03 | |
| 2010-06-30 | $2.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-26 | $40.86M 10-Q · filed 2011-07-26 | -$43.17M derived: sum of 3 quarters · filed 2012-02-03 | -$63.13M derived: sum of 4 quarters · filed 2012-02-03 | |
| 2010-03-31 | $38.04M 10-Q · filed 2011-04-21 | -$45.98M derived: sum of 2 quarters · filed 2012-02-03 | -$65.94M derived: sum of 3 quarters · filed 2012-02-03 | -$218.07M derived: sum of 4 quarters · filed 2012-02-03 | |
| 2009-12-31 | -$84.03M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03 | -$103.98M derived: sum of 2 quarters · filed 2012-02-03 | -$256.11M derived: sum of 3 quarters · filed 2012-02-03 | -$194.73M 10-K · filed 2012-02-03 | |
| 2009-09-30 | -$19.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-26 | -$172.08M derived: sum of 2 quarters · filed 2010-10-26 | -$110.71M 10-Q · filed 2010-10-26 | -$56.41M derived: sum of 4 quarters · filed 2011-02-04 | |
| 2009-06-30 | -$152.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2010-07-20 | -$90.75M 10-Q · filed 2010-07-20 | -$36.46M derived: sum of 3 quarters · filed 2011-02-04 | $81.73M derived: sum of 4 quarters · filed 2011-02-04 | |
| 2009-03-31 | $61.38M 10-Q · filed 2010-04-20 | $115.67M derived: sum of 2 quarters · filed 2011-02-04 | $233.85M derived: sum of 3 quarters · filed 2011-02-04 | ||
| 2008-12-31 | $54.29M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-04 | $172.48M derived: sum of 2 quarters · filed 2011-02-04 | $176.22M 10-K · filed 2011-02-04 | ||
| 2008-09-30 | $118.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2009-10-21 | $121.93M 10-Q · filed 2009-10-21 | |||
| 2008-06-30 | $3.74M 10-Q · filed 2009-07-17 | ||||
| 2007-12-31 | $41.29M 10-K · filed 2010-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |